{"entity":{"id":"insilico-medicine","kind":"company","name":"Insilico Medicine","aka":[],"tldr":"Generative-AI drug discovery company, listed in Hong Kong in December 2025, with a pan-KRAS candidate and a pan-TEAD inhibitor in the clinic.","summary":"Insilico's 2025 listing was the largest Hong Kong biotech IPO of the year (HKD 2.28B). Pipeline of 31 nominated candidates with 13 IND clearances; oncology assets include ISM6166 (pan-KRAS) and ISM6331 (pan-TEAD, phase 1 data at ESMO 2026 in mesothelioma and solid tumours). Profitable in H1 2026 on licensing revenue.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Insilico_Medicine","links":[{"label":"H1 2026 results","url":"https://www.biospace.com/press-releases/commercialization-roadmap-validated-with-three-digit-million-dollar-revenue-insilico-medicine-announces-interim-results-for-the-first-half-of-2026"}],"tags":[],"related":[],"cancers":["mesothelioma","pancreatic"],"sections":["ai-computation","drug-discovery"],"technologies":["ai-drug-design","kras-inhibitors"],"targets":["kras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06414460","nct06566079"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Hong Kong / Boston","country":"HK","companyType":"ai-software","website":"https://insilico.com","ticker":"3696.HK","investors":[],"funding":[]},"route":"/companies/insilico-medicine/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"chemistry42","kind":"technology","name":"Chemistry42 and Pharma.AI (Insilico)","route":"/technologies/chemistry42/"},{"id":"de-novo-protein-design","kind":"technology","name":"De novo designed protein binders","route":"/technologies/de-novo-protein-design/"},{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"trial":[{"id":"nct06414460","kind":"trial","name":"Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors","route":"/trials/nct06414460/"},{"id":"nct06566079","kind":"trial","name":"Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors","route":"/trials/nct06566079/"}],"bottleneck":[{"id":"b-translational-valley","kind":"bottleneck","name":"The valley of death between lab and product","route":"/bottlenecks/b-translational-valley/"}],"idea":[{"id":"idea-bio1-virtual-cell-perturbation","kind":"idea","name":"A virtual cancer cell that predicts what a drug will do before you test it","route":"/ideas/idea-bio1-virtual-cell-perturbation/"},{"id":"idea-bio1-in-silico-trials-dose","kind":"idea","name":"In silico trials to choose the dose before the first patient","route":"/ideas/idea-bio1-in-silico-trials-dose/"}],"roadmap":[{"id":"ai-oncology-roadmap","kind":"roadmap","name":"AI in oncology roadmap: pattern readers → foundation models → agents in the workflow","route":"/roadmaps/ai-oncology-roadmap/"},{"id":"drug-discovery-roadmap","kind":"roadmap","name":"Drug discovery roadmap: screening in mice → maps of dependency → designing in silico","route":"/roadmaps/drug-discovery-roadmap/"}]}}